KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Operating Expenses: 2020-2024

Historic Other Operating Expenses for CRISPR Therapeutics AG (CRSP) over the last 5 years, with Dec 2024 value amounting to $110.2 million.

  • CRISPR Therapeutics AG's Other Operating Expenses rose 412.10% to $57.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $267.2 million, marking a year-over-year increase of 105.13%. This contributed to the annual value of $110.2 million for FY2024, which is 15.36% down from last year.
  • CRISPR Therapeutics AG's Other Operating Expenses amounted to $110.2 million in FY2024, which was down 15.36% from $130.2 million recorded in FY2023.
  • CRISPR Therapeutics AG's Other Operating Expenses' 5-year high stood at $130.2 million during FY2023, with a 5-year trough of $48.0 million in FY2020.
  • For the 3-year period, CRISPR Therapeutics AG's Other Operating Expenses averaged around $116.9 million, with its median value being $110.2 million (2024).
  • Its Other Operating Expenses has fluctuated over the past 5 years, first spiked by 110.68% in 2021, then dropped by 15.36% in 2024.
  • CRISPR Therapeutics AG's Other Operating Expenses (Yearly) stood at $48.0 million in 2020, then skyrocketed by 110.68% to $101.2 million in 2021, then grew by 8.97% to $110.2 million in 2022, then increased by 18.14% to $130.2 million in 2023, then fell by 15.36% to $110.2 million in 2024.